Table 8 Identification of MPER specific neutralizing antibodies.

From: Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals

Chimera

MPER Sequence@

Neutralization

MAbs IC50*(μg/ml)

Plasma ID50 (1/dilutions)

2F5

4E10

Z13e1

240-D

NAB069

NAB120

NAB122

7312 A

NMYELQKLNSWDVFGNWFDLASWVKYIQYGVYIV

>10

>10

>10

>10

<20

<20

<20

C1 (clade B)

NMYELLALDKWASLWNWFDITKWLWYIKYGVYIV

0.016

0.0017

0.08

>10

5,074

<20

2,660

C1C (clade C)

NMYELLALD S W KN LWNWFDITKWLWYIKYGVYIV

>10

0.018

0.07

>10

12,960

<20

165.5

C6

NMYELQKLNSWDVFGNWFDITSWIKYIQYGVYIV

>10

0.013

>10

>10

2,504

<20

248.1

C7

NMYELQALDKWA VFGNWFDLASWVKYIQYGVYIV

0.07

>10

>10

>10

<20

<20

<20

  1. @HIV-1 MPER fragment substituted in the HIV-2 7312A virus.
  2. *Neutralization assay was performed with monoclonal antibodies 2F5, 4E10, Z13e1 as positive control and 240-D as negative control.
  3. Plasma ID50 was calculated against MPER grafted HIV-2 7312A viruses. The sequence carried by the MPER of each of the constructs is indicated in the second column. Mutated residues are indicated in bold (subtype B) and italic (subtype C).
  4. IC50 (μg/ml) formatted as <10; 15; >10.
  5. ID50 (dilutions) formatted as <20; 21500; >500.